SERPINE1, serpin family E member 1, 5054

N. diseases: 770; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Collectively, our findings provide support that PAI-1 contributes to the development of inflammation in perirenal fat and correlates with the development of diabetic nephropathy in HFD-induced obesity. 30532990 2019
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy. 26616527 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Therapeutic disease RGD Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. 26712211 2016
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE A meta-analysis was conducted to investigate the association between 4 G/5 G variants in the PAI-1 gene and DN susceptibility. 24345290 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Therefore, PAI-1R provides an additional therapeutic effect in slowing the progression of diabetic nephropathy via the protection of podocytes. 24443353 2014
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models. 24223897 2013
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease CTD_human Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. 18682491 2009
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE The ASO also reduced expression of genes involved in matrix expansion such as fibronectin and collagen (I and IV) and an inhibitor of matrix degradation, PAI-1, in the renal cortex, contributing to significant reversal of mesangial expansion in both models of DN. 17554073 2007
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE ThePAI1 gene is therefore an excellent candidate gene for diabetic nephropathy. 17263760 2007
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE The plasminogen activator inhibitor-1 (PAI-1) 4G/4G genotype influences the development of diabetic nephropathy and lupus nephritis. 15481848 2004
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease RGD Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor. 15322501 2004
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 AlteredExpression disease BEFREE Thus progression of diabetic nephropathy may be promoted by PAI-1 upregulation mediated by the glycated albumin-induced Smad/DNA interactions. 15198928 2004
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Neither the PAI-1 nor the ApoE gene polymorphism contributes to the genetic susceptibility to diabetic nephropathy or retinopathy. 10809802 2000
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Diabetic patients with coexistence of PAI-1 4G/4G genotype and ACE D alleles had a higher incidence of diabetic nephropathy (22 vs. 7%, P = 0.012) than those with other combinations of genotypes. 10652041 2000
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE We have examined the association of four candidate genes, angiotensin converting enzyme (ACE): insertion/deletion (I/D) polymorphism, plasminogen activator inhibitor-1 (PAI-1): 4G/5G polymorphism, decorin: 179/183/185 polymorphism and Werner syndrome helicase: C/R polymorphism, with the presence of diabetic nephropathy in Type 1 diabetic patients. 10495473 1999
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE These genes included (a) known regulators of mesangial cell activation in diabetic nephropathy (fibronectin, caldesmon, thrombospondin, and plasminogen activator inhibitor-1), (b) novel genes, and (c) known genes whose induction by high glucose has not been reported. 10026205 1999
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 GeneticVariation disease BEFREE Using multivariate logistic regression analyses, we investigated the independent or synergistic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on the development of diabetic nephropathy and macroangiopathy in 208 patients with non-insulin dependent diabetes mellitus (NIDDM) over a 15 year period. 9844142 1998
CUI: C0011881
Disease: Diabetic Nephropathy
Diabetic Nephropathy
0.600 Biomarker disease BEFREE Protein and mRNA expression of TGF-beta isoforms, TGF-beta 1, -beta 2 and -beta 3, and deposition of fibronectin containing extra domain A (fibronectin EDA+) and plasminogen activator inhibitor-1 (PAI-1) were studied in human chronic glomerulonephritis and diabetic nephropathy. 8821830 1996